Tripos Awarded Second U.S. Patent for Novel Predictive Computational Method

HQSAR Provides Rapid and Simplified Determination of

Structure-Activity Relationships



Apr 27, 2001, 01:00 ET from Tripos, Inc.

    ST. LOUIS, April 27 /PRNewswire/ -- Tripos, Inc. (Nasdaq:   TRPS) today
 announced that it has been awarded patent number 6208942 entitled, "Molecular
 Hologram QSAR" by the United States Patent and Trademark Office. The new
 patent protects a novel Tripos technology for automatic examination of
 molecules to identify their structural characteristics responsible for
 biological activity. This technology is the foundation for HQSAR(TM), a
 component of the SYBYL(R) complete computational environment for molecular
 design and analysis. HQSAR is widely used in the pharmaceutical, agrochemical,
 and biotechnology industries for the design of new molecules tailored to have
 a specific biological activity.
     In molecular hologram quantitative structure-activity relationships
 (HQSAR), molecules are described in terms of fragments that implicitly encode
 3-D information. Sophisticated statistical methods are employed to determine
 which of these fragments are responsible for a molecule's behavior. Using the
 results of HQSAR analyses, scientists can predict the biological activity of
 untested molecules, saving research time and expediting the discovery and
 development of new drugs. This patent is the second to recognize HQSAR
 technology and supports Tripos' first HQSAR patent, number 5751605, also
 entitled "Molecular Hologram QSAR." The first patent recognizes the
 methodological invention, while the new patent acknowledges the incorporation
 of explicit stereochemical information in HQSAR's molecular descriptors.
     "HQSAR generates high quality QSAR models with predictive capabilities
 comparable to those of more complex 3D-QSAR techniques," commented Dr. Trevor
 Heritage, Senior Vice President-Discovery Technology at Tripos, one of the
 inventors. "Unlike other 3D-QSAR methods, HQSAR does not require that
 molecules be aligned prior to analysis. This reduction in complexity means
 that HQSAR can be automated for straightforward analysis of very large numbers
 of molecules. Scientists can save precious research time by automatically
 extracting knowledge from existing compounds to guide the design of
 next-generation drugs."
     "Tripos' second HQSAR patent demonstrates our continued commitment to
 creating innovative, efficient technologies that expedite our customers'
 research efforts. We focus on developing validated, predictive solutions for
 scientists to measurably reduce the customary timelines for discovering new
 products," said Dr. John P. McAlister, President and CEO of Tripos. "HQSAR is
 just the latest of many novel developments to flow from Tripos' twenty-year
 legacy of continuous scientific innovation."
 
     About Tripos
     Tripos (http://www.tripos.com) is a leading provider of discovery research
 software and services to pharmaceutical, biotechnology, and other life
 sciences companies worldwide. The company is dedicated to simplifying and
 accelerating the discovery of new products in the pharmaceutical and related
 industries.  Tripos offers "chemically intelligent" discovery software tools
 to manage, analyze, and share biological and chemical information; systems
 integration and other software consulting services; diverse chemical libraries
 and contract research for the discovery, synthesis and characterization of new
 chemical compounds that are active in biological systems.
 
     For further information, contact:
     Denise Beusen, Ph.D.
     Discovery Software Marketing Manager
     Tripos, Inc.
     314-647-1099
     dbeusen@tripos.com
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X36857933
 
 

SOURCE Tripos, Inc.
    ST. LOUIS, April 27 /PRNewswire/ -- Tripos, Inc. (Nasdaq:   TRPS) today
 announced that it has been awarded patent number 6208942 entitled, "Molecular
 Hologram QSAR" by the United States Patent and Trademark Office. The new
 patent protects a novel Tripos technology for automatic examination of
 molecules to identify their structural characteristics responsible for
 biological activity. This technology is the foundation for HQSAR(TM), a
 component of the SYBYL(R) complete computational environment for molecular
 design and analysis. HQSAR is widely used in the pharmaceutical, agrochemical,
 and biotechnology industries for the design of new molecules tailored to have
 a specific biological activity.
     In molecular hologram quantitative structure-activity relationships
 (HQSAR), molecules are described in terms of fragments that implicitly encode
 3-D information. Sophisticated statistical methods are employed to determine
 which of these fragments are responsible for a molecule's behavior. Using the
 results of HQSAR analyses, scientists can predict the biological activity of
 untested molecules, saving research time and expediting the discovery and
 development of new drugs. This patent is the second to recognize HQSAR
 technology and supports Tripos' first HQSAR patent, number 5751605, also
 entitled "Molecular Hologram QSAR." The first patent recognizes the
 methodological invention, while the new patent acknowledges the incorporation
 of explicit stereochemical information in HQSAR's molecular descriptors.
     "HQSAR generates high quality QSAR models with predictive capabilities
 comparable to those of more complex 3D-QSAR techniques," commented Dr. Trevor
 Heritage, Senior Vice President-Discovery Technology at Tripos, one of the
 inventors. "Unlike other 3D-QSAR methods, HQSAR does not require that
 molecules be aligned prior to analysis. This reduction in complexity means
 that HQSAR can be automated for straightforward analysis of very large numbers
 of molecules. Scientists can save precious research time by automatically
 extracting knowledge from existing compounds to guide the design of
 next-generation drugs."
     "Tripos' second HQSAR patent demonstrates our continued commitment to
 creating innovative, efficient technologies that expedite our customers'
 research efforts. We focus on developing validated, predictive solutions for
 scientists to measurably reduce the customary timelines for discovering new
 products," said Dr. John P. McAlister, President and CEO of Tripos. "HQSAR is
 just the latest of many novel developments to flow from Tripos' twenty-year
 legacy of continuous scientific innovation."
 
     About Tripos
     Tripos (http://www.tripos.com) is a leading provider of discovery research
 software and services to pharmaceutical, biotechnology, and other life
 sciences companies worldwide. The company is dedicated to simplifying and
 accelerating the discovery of new products in the pharmaceutical and related
 industries.  Tripos offers "chemically intelligent" discovery software tools
 to manage, analyze, and share biological and chemical information; systems
 integration and other software consulting services; diverse chemical libraries
 and contract research for the discovery, synthesis and characterization of new
 chemical compounds that are active in biological systems.
 
     For further information, contact:
     Denise Beusen, Ph.D.
     Discovery Software Marketing Manager
     Tripos, Inc.
     314-647-1099
     dbeusen@tripos.com
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X36857933
 
 SOURCE  Tripos, Inc.